Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022

$1.09
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.04 (+3.80%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can watch OTLKW and buy or sell other stocks, options, and ETFs commission-free!

About OTLKW

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification, development, manufacture, and commercialization of ONS-5010/LYTENAVA as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in South Brunswick, NJ. The listed name for OTLKW is Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022.

CEO
Lawrence A. Kenyon, CPA
Employees
—
Headquarters
South Brunswick, New Jersey
Founded
2010
Market Cap
—
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
215.90K
High Today
$1.15
Low Today
$1.06
Open Price
$1.11
Volume
69.41K
52 Week High
$3.49
52 Week Low
$0.0501

You May Also Like

YGMZ
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure